TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01733589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human endostatin
Description: Recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7,combined with concurrent chemo-radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatinum (50mg/m2) IV (in the vein) on day 1 and day 8 of a 28-day cycle for 2 cycles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT perfusion imaging
Study: NCT01010204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
Study: NCT02530697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine antimoniate
Description: 20mgSb+5/kg/day meglumine antimoniate intravenous for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meglumine antimoniate
Description: 20mgSb+5/kg/day meglumine antimoniate intravenous for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: Miltefosine 2,5mg/kg/day up to 50mg 2x/daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: Miltefosine 2,5mg/kg/day up to 50mg 2x/daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: Pentoxifylline 20mg/kg/day up to 400mg 3x/daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline 20mg/kg/day up to 400mg 3x/daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline 20mg/kg/day up to 400mg 3x/daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline 20mg/kg/day up to 400mg 3x/daily for 28 days.
Study: NCT01733992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R348 Ophthalmic Solution, 0.2%
Description: R348 Ophthalmic Solution, 0.2% single and multiple ascending dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R348 Ophthalmic Solution, 0.5%
Description: R348 Ophthalmic Solution, 0.5%, single and multiple ascending dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R348 Ophthalmic Solution, 1.0%
Description: R348 Ophthalmic Solution, 1.0%, single and multiple ascending dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, single and multiple ascending dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, single and multiple ascending dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, single and multiple ascending dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, single and multiple ascending dose
Study: NCT02128334

Intervention type: DRUG
Intervention: Eligard 45 mg Exposure
Description: Subcutaneous injections
Study: NCT03642600

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dietary advice plus myo-inositol and folic acid
Description: dietary advice and lifestyle interventions and myo-inositol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dietary advice plus Liraglutide Pen Injector
Description: dietary advice and lifestyle interventions and liraglutide pen injector
Study: NCT03688802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC-01 (varenicline) nasal spray
Description: OC-01 (varenicline) nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle control) nasal spray
Description: Placebo
Study: NCT04059341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT)
Description: Five sessions of penile Low Intensity Extracorporeal Shockwave Therapy initiated three weeks after radical prostatectomy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT)
Description: Five sessions of penile Low Intensity Extracorporeal Shockwave Therapy initiated three weeks after radical prostatectomy.
Study: NCT03208413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.
Study: NCT02278705

Intervention type: OTHER
Intervention: Attention to BMI
Description: Evidence (using electronic health record data) denoting provider attention to about high BMI.

Intervention type: OTHER
Intervention: Attention to BMI
Description: Evidence (using electronic health record data) denoting provider attention to about high BMI.

Intervention type: OTHER
Intervention: Attention to high-BMI-related Medical Risk
Description: Evidence (using electronic health record data) denoting provider attention to high-BMI-related medical risk, including from high blood pressure/hypertension, cholesterol/dyslipidemia, blood sugar/diabetes, liver enzymes/fatty liver, and low vitamin D/vitamin-D deficiency.

Intervention type: OTHER
Intervention: Attention to high-BMI-related Medical Risk
Description: Evidence (using electronic health record data) denoting provider attention to high-BMI-related medical risk, including from high blood pressure/hypertension, cholesterol/dyslipidemia, blood sugar/diabetes, liver enzymes/fatty liver, and low vitamin D/vitamin-D deficiency.

Intervention type: OTHER
Intervention: No attention to high BMI or high-BMI-related medical risk
Description: Lack of evidence (using electronic health record data) denoting provider attention to high BMI or high-BMI-related medical risk.

Intervention type: OTHER
Intervention: No attention to high BMI or high-BMI-related medical risk
Description: Lack of evidence (using electronic health record data) denoting provider attention to high BMI or high-BMI-related medical risk.
Study: NCT04137341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 - A
Description: Film-coated tablet, formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 - B
Description: Film-coated tablet, formulation B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 - B
Description: Film-coated tablet, formulation B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 - C
Description: Film-coated tablet, formulation C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 - C
Description: Film-coated tablet, formulation C
Study: NCT02940873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HARPdoc courses
Description: A six week group education package including hypoglycaemia-focussed cognitive behavioural therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BGAT courses
Description: A structured psycho-education programme focussing on better prediction and recognition of high and low blood glucose values
Study: NCT02587754

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: 10 sessions of acupuncture, twice a week over 5 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: 10 sessions of acupuncture, twice a week over 5 weeks.
Study: NCT01381380

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Manual therapy
Description: Manual therapy, once a week for 8 weeks
Study: NCT03549065

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brain Stimulation
Description: Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation method that stimulates the brain of an individual focally(George \& Belmaker, 2007). TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS).~Transcranial direct current stimulation (tDCS) is another form of non-invasive brain stimulation that is being investigated as an intervention for neurological and psychiatric disorders. A weak direct electrical current (0-2 mA) flows between two small electrodes via saline soaked sponges placed on the scalp (Nitsche MA et al, 2008).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brain Stimulation
Description: Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation method that stimulates the brain of an individual focally(George \& Belmaker, 2007). TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS).~Transcranial direct current stimulation (tDCS) is another form of non-invasive brain stimulation that is being investigated as an intervention for neurological and psychiatric disorders. A weak direct electrical current (0-2 mA) flows between two small electrodes via saline soaked sponges placed on the scalp (Nitsche MA et al, 2008).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brain Stimulation
Description: Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation method that stimulates the brain of an individual focally(George \& Belmaker, 2007). TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS).~Transcranial direct current stimulation (tDCS) is another form of non-invasive brain stimulation that is being investigated as an intervention for neurological and psychiatric disorders. A weak direct electrical current (0-2 mA) flows between two small electrodes via saline soaked sponges placed on the scalp (Nitsche MA et al, 2008).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Brain Stimulation
Description: Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation method that stimulates the brain of an individual focally(George \& Belmaker, 2007). TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS).~Transcranial direct current stimulation (tDCS) is another form of non-invasive brain stimulation that is being investigated as an intervention for neurological and psychiatric disorders. A weak direct electrical current (0-2 mA) flows between two small electrodes via saline soaked sponges placed on the scalp (Nitsche MA et al, 2008).
Study: NCT00253370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 43-9006
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study: NCT01634568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V81444
Description: Single ascending oral doses of V81444 and placebo~Multiple ascending oral doses of V81444 and placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V81444
Description: Single ascending oral doses of V81444 and placebo~Multiple ascending oral doses of V81444 and placebo
Study: NCT02483494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APN-led Telemedicine
Description: Allocation to experimental or Usual care is 1:1.~The four study APNs will be delivering the care and have at least three years working experiences in coronary care settings. A telephonic script and study protocol is made available to ensure standardization of intervention.
Study: NCT01308996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INFUSE® Bone Graft
Description: Implantation of INFUSE® Bone Graft \[recombinant human Bone Morphogenetic Protein-2 (rhBMP-2)\] and absorbable collagen sponge (ACS) carrier at 1.50 mg/cc with space maintenance device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone graft from tibia or iliac crest
Description: Implantation of autogenous bone graft from iliac crest or tibia with titanium mesh space maintenance device
Study: NCT01010204

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
Study: NCT00919945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous feeding at time 1 and NPO at time 2
Description: Continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 1 and NPO at time 2 (12 hours later)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NPO at time 1 and continuous feeding at time 2
Description: NPO at time 1 and continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 2 (12 hours later).
Study: NCT03186586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate
Description: 5mg/day/five days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one pill a day for 5 days at the bleeding episode
Study: NCT00535938

Intervention type: OTHER
Intervention: botulinum toxin type A
Description: There will be no protocol-mandated intervention with regard to physician treatment choice or management of patient condition once the patient is enrolled in the project.

Intervention type: OTHER
Intervention: botulinum toxin type A
Description: There will be no protocol-mandated intervention with regard to physician treatment choice or management of patient condition once the patient is enrolled in the project.
Study: NCT03457974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saliva
Description: salivary secretion rate, salivary buffering capacity, pH, protein levels, superoxide dismutase (SOD), ferric reducing antioxidant power (FRAP), the thiobarbituric acid reactive substances (TBARS), protein carbonyl, protein thiols, total sialic acid.

Intervention type: OTHER
Group type: OTHER
Intervention: saliva
Description: salivary secretion rate, salivary buffering capacity, pH, protein levels, superoxide dismutase (SOD), ferric reducing antioxidant power (FRAP), the thiobarbituric acid reactive substances (TBARS), protein carbonyl, protein thiols, total sialic acid.
Study: NCT04136600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR antibody and Chemotherapy
Description: Drug: Cetuximab Cetuximab: 500 mg/m2 iv on Day 1 of cycle every 3 weeks, until disease progression.~Other Names:~Erbitux Drug: Nimotuzumab Nimotuzumab: 400mg iv on Day 1 of cycle, every week, until disease progression~Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles~Other Names:~5-Fu Drug: Capecitabine Capecitabine: 1000 mg/m2 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~Xeloda Drug: S-1 S-1: 60mg for BSA\>1.5, 50 mg for 1.5\>BSA\>1.25 , 40mg for BSA\<1.25 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~S-1 Drug: Oxaliplatin Oxaliplatin: 85 mg/m2 iv on Day 1 of cycle, every 2 week for 12 cycles with 5-Fu; Oxaplatin: 130 mg/m2 iv on Day 1 of cycle, every 3 week for 6 cycles combined with S-1 or Capecitabine;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles~Other Names:~5-Fu Drug: Capecitabine Capecitabine: 1000 mg/m2 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~Xeloda Drug: S-1 S-1: 60mg for BSA\>1.5, 50 mg for 1.5\>BSA\>1.25 , 40mg for BSA\<1.25 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~S-1 Drug: Oxaliplatin Oxaliplatin: 85 mg/m2 iv on Day 1 of cycle, every 2 week for 12 cycles with 5-Fu; Oxaplatin: 130 mg/m2 iv on Day 1 of cycle, every 3 week for 6 cycles combined with S-1 or Capecitabine;
Study: NCT03310671

Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: Conventional transthoracic echocardiogram by an echocardiographer trained to perform and centered on aortic valve~Pick up from:~* Mean transvalvular pressure gradient~* Aortic valve~* Aortic valve opening area~* Aortic valve opening area adjusted for body mass index~* Bicuspid or tricuspid aorta~* Thickness of the upper valve\> 3 mm

Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: Conventional transthoracic echocardiogram by an echocardiographer trained to perform and centered on aortic valve~Pick up from:~* Mean transvalvular pressure gradient~* Aortic valve~* Aortic valve opening area~* Aortic valve opening area adjusted for body mass index~* Bicuspid or tricuspid aorta~* Thickness of the upper valve\> 3 mm
Study: NCT01646528

Intervention type: PROCEDURE
Intervention: CLE examination for upper gastrointestinal tract
Description: Routine upper GI endoscopy plus targeted CLE examination
Study: NCT01517607

Intervention type: OTHER
Intervention: Mesalazine
Description: Patient's treated with oral Mesalazine
Study: NCT05889949

Intervention type: DRUG
Intervention: Sorafenib
Description: oral sorafenib

Intervention type: DRUG
Intervention: Lenvatinib
Description: oral lenvatinib
Study: NCT02652195

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intranasal administration, 3 puffs per nostril, delivered prior to scanning session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff, delivered prior to scanning session.
Study: NCT04601597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shu Bei Kang (China) Midline Catheters
Description: The procedures ① evaluation and selection of blood vessels: select the puncture vein in the middle of the patient's upper arm, ② Skin disinfection and towel laying: take the supine position, extend the upper limb to be punctured 45 \~ 90 °, disinfect the pre punctured upper limb with 75% alcohol and 5% povidone iodine. ③ Puncture vein: tie a tourniquet to fill the vein. Before puncture, use 0.2 \~ 0.4 ml of 2% lidocaine for local anesthesia. Under the guidance of ultrasound, use the puncture needle in the improved sedinger assembly for puncture. After successful puncture, insert the guide wire. ④ Delivery and confirmation of catheter position: after successful puncture, insert the dilator catheter sheath assembly, withdraw the setinger guide wire, deliver the catheter, after catheter placement, flush and seal the catheter with normal saline, and fix the catheter with sterile dressing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shu Bei Kang (China) Midline Catheters
Description: The procedures ① evaluation and selection of blood vessels: select the puncture vein in the middle of the patient's upper arm, ② Skin disinfection and towel laying: take the supine position, extend the upper limb to be punctured 45 \~ 90 °, disinfect the pre punctured upper limb with 75% alcohol and 5% povidone iodine. ③ Puncture vein: tie a tourniquet to fill the vein. Before puncture, use 0.2 \~ 0.4 ml of 2% lidocaine for local anesthesia. Under the guidance of ultrasound, use the puncture needle in the improved sedinger assembly for puncture. After successful puncture, insert the guide wire. ④ Delivery and confirmation of catheter position: after successful puncture, insert the dilator catheter sheath assembly, withdraw the setinger guide wire, deliver the catheter, after catheter placement, flush and seal the catheter with normal saline, and fix the catheter with sterile dressing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shu Bei Kang (China) Midline Catheters
Description: The procedures ① evaluation and selection of blood vessels: select the puncture vein in the middle of the patient's upper arm, ② Skin disinfection and towel laying: take the supine position, extend the upper limb to be punctured 45 \~ 90 °, disinfect the pre punctured upper limb with 75% alcohol and 5% povidone iodine. ③ Puncture vein: tie a tourniquet to fill the vein. Before puncture, use 0.2 \~ 0.4 ml of 2% lidocaine for local anesthesia. Under the guidance of ultrasound, use the puncture needle in the improved sedinger assembly for puncture. After successful puncture, insert the guide wire. ④ Delivery and confirmation of catheter position: after successful puncture, insert the dilator catheter sheath assembly, withdraw the setinger guide wire, deliver the catheter, after catheter placement, flush and seal the catheter with normal saline, and fix the catheter with sterile dressing.
Study: NCT02274077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT00988533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Ivermectin Cream
Description: Topical 0.5% ivermectin cream applied to scalp and hair on day 1
Study: NCT00943722

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.